AZNAstraZenecaRunning, no new patients
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 390 (final count)
- Started
- Feb 21, 2022
- Main results expected
- Aug 2, 2027
- Fully finished
- Nov 1, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Disease-Free Survival (DFS) in high-risk stratum
Measured over: From date of randomisation up to approximately 10 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05120349 · record last updated 2026-07-06 · checked 2026-11-09 15:47 UTC